357 related articles for article (PubMed ID: 31067633)
1. A Comprehensive Bioinformatics Analysis of
Dastsooz H; Cereda M; Donna D; Oliviero S
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31067633
[TBL] [Abstract][Full Text] [Related]
2. Combined elevation of AURKB and UBE2C predicts severe outcomes and therapy resistance in glioma.
Alafate W; Zuo J; Deng Z; Guo X; Wu W; Zhang W; Xie W; Wang M; Wang J
Pathol Res Pract; 2019 Oct; 215(10):152557. PubMed ID: 31353228
[TBL] [Abstract][Full Text] [Related]
3. UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines.
Palumbo A; Da Costa NM; De Martino M; Sepe R; Pellecchia S; de Sousa VP; Nicolau Neto P; Kruel CD; Bergman A; Nasciutti LE; Fusco A; Pinto LF
Oncotarget; 2016 Oct; 7(40):65876-65887. PubMed ID: 27588470
[TBL] [Abstract][Full Text] [Related]
4. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression.
Ieta K; Ojima E; Tanaka F; Nakamura Y; Haraguchi N; Mimori K; Inoue H; Kuwano H; Mori M
Int J Cancer; 2007 Jul; 121(1):33-8. PubMed ID: 17354233
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data.
Mo CH; Gao L; Zhu XF; Wei KL; Zeng JJ; Chen G; Feng ZB
Cancer Cell Int; 2017; 17():83. PubMed ID: 29021715
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker.
Xie C; Powell C; Yao M; Wu J; Dong Q
Int J Biochem Cell Biol; 2014 Feb; 47():113-7. PubMed ID: 24361302
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients.
Zhang HQ; Zhao G; Ke B; Ma G; Liu GL; Liang H; Liu LR; Hao XS
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1665-1671. PubMed ID: 29630110
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker.
Hao Z; Zhang H; Cowell J
Tumour Biol; 2012 Jun; 33(3):723-30. PubMed ID: 22170434
[TBL] [Abstract][Full Text] [Related]
9. Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target.
Huang GZ; Chen ZQ; Wu J; Shao TR; Zou C; Ai YL; Lv XZ
J Immunol Res; 2021; 2021():9250207. PubMed ID: 34950739
[TBL] [Abstract][Full Text] [Related]
10. Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.
Martínez-Canales S; López de Rodas M; Nuncia-Cantarero M; Páez R; Amir E; Győrffy B; Pandiella A; Galán-Moya EM; Ocaña A
Cancer Med; 2018 May; 7(5):1896-1907. PubMed ID: 29575713
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of UBE2C gene in progression of renal cell carcinoma.
Chen Z; Wang L
Eur J Histochem; 2021 Mar; 65(2):. PubMed ID: 33782624
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma.
Ong KH; Lai HY; Sun DP; Chen TJ; Huang SK; Tian YF; Chou CL; Shiue YL; Chan TC; Li CF; Kuo YH
Eur J Med Res; 2023 Dec; 28(1):593. PubMed ID: 38102624
[TBL] [Abstract][Full Text] [Related]
13. System analysis identifies UBE2C as a novel oncogene target for adrenocortical carcinoma.
Huang R; Guo L; Chen C; Xiang Y; Li G; Zheng J; Wu Y; Yuan X; Zhou J; Gao W; Xiang S
PLoS One; 2023; 18(8):e0289418. PubMed ID: 37535572
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of UBE2C in endometrial cancer and its correlation to epithelial mesenchymal transition.
Zhang Y; Li X; Gong Y; Du D; Chen H; Liu L; Cheng Z
Medicine (Baltimore); 2023 May; 102(20):e33834. PubMed ID: 37335710
[TBL] [Abstract][Full Text] [Related]
15. UBE2C: A pan-cancer diagnostic and prognostic biomarker revealed through bioinformatics analysis.
Jalali P; Samii A; Rezaee M; Shahmoradi A; Pashizeh F; Salehi Z
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2032. PubMed ID: 38577722
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Ubiquitin-Conjugating Enzyme E2C Is Associated with Worsened Prognosis in Prostate Cancer.
Wu X; Long X; Ma C; Cheuk YC; Hu M; Hu J; Jiang H
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430352
[TBL] [Abstract][Full Text] [Related]
17. UBE2C is a diagnosis and therapeutic biomarker involved in immune infiltration of cancers including lung adenocarcinoma.
Cai D; Tian F; Wu M; Tu J; Wang Y
J Cancer; 2024; 15(6):1701-1717. PubMed ID: 38370368
[TBL] [Abstract][Full Text] [Related]
18. Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH.
Takahashi Y; Ishii Y; Nishida Y; Ikarashi M; Nagata T; Nakamura T; Yamamori S; Asai S
Cancer Genet Cytogenet; 2006 Jul; 168(1):30-5. PubMed ID: 16772118
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.
Kariri Y; Toss MS; Alsaleem M; Elsharawy KA; Joseph C; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2022 Apr; 192(3):529-539. PubMed ID: 35124721
[TBL] [Abstract][Full Text] [Related]
20. High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma.
Ma R; Kang X; Zhang G; Fang F; DU Y; Lv H
Oncol Lett; 2016 Mar; 11(3):2300-2304. PubMed ID: 26998166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
